A breakthrough study has just supercharged Fusarium venenatum (the fungus used in mycoprotein products like Quorn), turning ...
The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...
Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor ...
CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, ...
Crispr Therapeutics (CRSP) quickly rose 1.3% amid some takeover speculation. Crispr (CRSP) is said to have attracted takeover ...
An experimental gene-editing treatment shows promise for permanently lowering levels of cholesterol and triglycerides, ...
By reactivating a long-lost gene, researchers were able to lower uric acid levels and stop damaging fat accumulation in human ...
CRISPR has turned a simple fungus into a fast-growing, meat-like protein source with impressively low environmental impact.
The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. | The patient who was ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...
CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results